Navigation Links
DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3)

s, with antibody discovery facilities in Liege, Belgium. For online information about Dyax Corp., please visit www.dyax.com.

Dyax Disclaimer

This press release contains forward-looking statements, including statements regarding clinical trials, the potential administration, dosing, safety and therapeutic benefit of DX-88 for HAE. Statements that are not historical facts are based on Dyax's current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect clinical trials, the potential administration, dosing and therapeutic benefit of DX-88 for HAE, include the risks that: DX-88 may not show sufficient therapeutic effect or an acceptable safety profile in clinical trials or could take a significantly longer time to gain regulatory approval than Dyax expects or may never gain approval; others may develop technologies or products superior to DX-88 or that are on the market before DX-88; DX-88 may not gain market acceptance; Dyax is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacture, marketing, sales and distribution of DX-88; and other risk factors described or referred to Item 1A, "Risk Factors" in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
3. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
7. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
8. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
Post Your Comments:
(Date:7/29/2014)... York , July 29, 2014 ... Transparency Market Research "Surgical Navigation Systems Market (Neurosurgical Navigation ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... was valued at USD 218.5 million in 2013 and ... from 2014 to 2020, to reach an estimated value ...
(Date:7/29/2014)... LAUDERDALE, Fla. , July 29, 2014 /PRNewswire-iReach/ ... medical service provider, has launched its Medical ... Program.  These services are tailored to the ... excellent standards prompted industry operators to propose that ... MHG Medical,s new program is intended to ...
(Date:7/29/2014)... BEDFORD, Mass. , July 29, 2014  Instrumentation Laboratory ... identity, including a new corporate logo. This is part of ... IL. Founded in Boston, MA ... Group family of companies since 1992.  Other companies in the ... ), Biokit and Systelab ( Barcelona, Spain ).  ...
Breaking Medicine Technology:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3
(Date:7/29/2014)... 2014 The Natural Multiple Sclerosis Treatment ... story to Gary M. Levin’s cure program. , ... for this serious disorder. Levin says that multiple sclerosis ... can be found in patients. , Dr. Gary ... many years, Levin has worked with patients suffering from ...
(Date:7/29/2014)... Winter is here down under, and ... Sydney’s central business district. That is, until a troop ... the otherwise ordinary day into a celebration—a celebration of ... advocates of The Truth About Drugs, a drug prevention ... They woke up the city with a rousing performance ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... is a 5 step holistic system that will permanently eliminate ... to Thomas Coleman his natural treatment will banish symptoms such ... ringing or beeping sound heard by patients will be gone ... 30 to 60 days. The author of this program says ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) --,The time at which ... their chances for survival, new research suggests. Showing ... or during holidays is associated with a 13 percent ... hours, researchers report. Every year, more than 250,000 ... severe type of heart attack, which is caused by ...
(Date:7/29/2014)... Although the bite of a brown recluse spider is ... an expert notes. It,s still important to recognize ... brown recluse spider bite, warned Dr. Donna Seger, medical ... potentially dangerous bites are on the rise. "As ... The [bite] has classic characteristics, but if physicians are ...
Breaking Medicine News(10 mins):Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2
... HealthDay Reporter , THURSDAY, Oct. 27 (HealthDay News) ... speech therapy after suffering a massive stroke at the age ... a year-and-a-half completely isolated, unable to communicate, socialize or work ... in Texas, one of a handful of organizations cropping up ...
... , THURSDAY, Oct. 27 (HealthDay News) -- Nipple-sparing ... patients and women who have their breasts removed because ... a new study. For both groups of women, ... feeling reconstructed breast compared to other types of mastectomy, ...
... By Ellin Holohan HealthDay Reporter , ... a lifetime of problems after suffering head injuries from ... new study. From communication deficits to trouble with ... injuries can lead to "substantial long-term reduction" in quality ...
... Whitehead Institute scientists have determined that master transcription factors ... this way, signaling pathways are targeted to genes that ... gene expression to control cell state, growth, differentiation, and ... operate properly, a cell receives instructions from its neighbors ...
... of Nursing (NYUCN) received a two-year, $299,990.00 grant from ... (NCSBN) to research the "Impact of an Internationally Educated ... Nursing Homes." According to the Principal Investigator, Laura ... the NCSBN,s Patient Safety, Practice (LPN/VN, RN), and International ...
... By Maureen Salamon HealthDay Reporter , THURSDAY, Oct. 27 ... its frequent companion, drinking, may be as well, a new study ... week find a link between heavy boozing and a rise in ... hand, studies also suggest that heavier people are less likely to ...
Cached Medicine News:Health News:Speech Therapy Key to Stroke Rehab, But Many Miss Out 2Health News:Speech Therapy Key to Stroke Rehab, But Many Miss Out 3Health News:Nipple-Sparing Mastectomies May Be Right for Some 2Health News:Children With Head Injuries Can Face Lifetime of Problems 2Health News:Children With Head Injuries Can Face Lifetime of Problems 3Health News:How major signaling pathways are wired to our genome gives new insight into disease processes 2Health News:How major signaling pathways are wired to our genome gives new insight into disease processes 3Health News:Too Much Drinking May Raise Lung Cancer Risk: Study 2Health News:Too Much Drinking May Raise Lung Cancer Risk: Study 3
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
MBP's 200 L large orifice tip is perfect for handling fragile cells, viscous samples and genomic....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
Medicine Products: